OK
OnKure Therapeutics, Inc.
OKUR · NASDAQ
$2.95 -0.34% (-$0.01)
1M -25.13%
Market Cap $119.9M
P/E Ratio -
Div. Yield -
ROE 49.02%
Bulios Fair Price
$2.06
30.2% downside
Current Price
$2.95
Undervalued Fair Value Overvalued
According to Bulios Fair Price, OKUR is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/B 0.70x
EV/EBITDA N/A
P/S N/A
Growth
-
N/A Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 49.02%
ROA 32.73%
Asset turnover 0.00x
Debt
69 /100
Low Current ratio 26.75x
Int. coverage -7,337.12x
Debt/Equity 0.01x
Stability
48 /100
Moderate EPS volatility 19.75%
Profitable years 0
Beta 0.30x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about OKUR
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Nicholas A. Saccomano
Employees
45
Headquarters
Boulder
Upcoming events
05 NOV
Earnings
Upcoming earnings report